Ziccum CEO Ann Gidner will present Ziccum’s unique drying technology for biopharmaceuticals, LaminarPace, and its market potential at BioFuture 2023. Uniquely, LaminarPace enables new delivery and greatly improved stability for biopharmaceuticals, potentially making new treatments available for patients world-wide. Most importantly, the enormous potential of the mRNA/LNP therapy and vaccine platform could be unlocked if delivery and stability challenges were solved. Ziccum presented excellent data in mRNA/LNP trials during spring 2023, followed by two prestigious industrial feasibility agreements being signed.

Driven by public & private initiatives, BioFuture has emerged as a hub for innovation in the life sciences and digital health space. LifeSciNY is allocating 500 MUSD in investment to build the Life Science arena.

Ziccum has been represented at a series of high-profile industry events throughout the year – including the Global mRNA Therapeutic Summit in Boston, Mass. and the invitation-only Longwood Healthcare Leaders Spring Conference. In June / July, Ziccum reported signing two major new Evaluation Agreements for Feasibility Studies for mRNA/LNP projects with major Pharmaceutical/Biotech corporations leading the mRNA-field.

Ann Gidner: “it is exciting to participate at BioFuture in New York. We are proud to be presenting the Ziccum core concept, successful data and the very significant mRNA market outlook to US investors, taking a next step in our international outreach”.